Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06328777 · ClinicalTrials.gov registry record · Phase 1
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
A Phase 1 study of Systemic Sclerosis and Scleroderma, sponsored by Cabaletta Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 10
- Study locations
NCT06328777 is a Phase 1 study of Systemic Sclerosis and Scleroderma that is actively recruiting participants, run by Cabaletta Bio. The registered enrollment target is 12 participants, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06328777, a Phase 1 study of Systemic Sclerosis and Scleroderma, is actively recruiting participants, sponsored by Cabaletta Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 10
- Study locations
Study Summary
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Conditions Studied
Interventions
- BIOLOGICAL CABA-201
Study Locations (10)
Illinois
- Northwestern Memorial Hospital - Chicago
- The University of Chicago Medical Center - Chicago
New York
- Columbia University Irving Medical Center - New York
- University of Rochester - Rochester
Connecticut
- Yale University - New Haven
Florida
- Mayo Clinic Florida - Jacksonville
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic Rochester - Rochester
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06328777
The ClinicalTrials.gov registry entry for NCT06328777 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Cabaletta Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which CABA-201 is the first listed.
NCT06328777 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Illinois, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06328777 about?
NCT06328777 is a clinical study titled "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis". RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
What is the current status of trial NCT06328777?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-07-02. Estimated completion is 2029-07.
What conditions does trial NCT06328777 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Scleroderma.
What interventions are being tested in trial NCT06328777?
The interventions under investigation include: CABA-201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06328777?
This trial is sponsored by Cabaletta Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06328777 being conducted?
This trial has 10 study locations across Connecticut, Florida, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RECRUITING · Phase 1
-
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.